THIRD AMENDMENT TO CONSULTANCY AGREEMENTConsultancy Agreement • December 29th, 2022 • 180 Life Sciences Corp. • Pharmaceutical preparations
This Third Amendment to Consultancy Agreement (this “Amendment”), dated December 28, 2022 (the “Effective Date”), amends that certain Consultancy Agreement dated February 22, 20211, amended by the First Amendment to Consultancy Agreement dated March 31, 2021 and effective as of December 1, 20202 and the Second Amendment to Consultancy Agreement dated April 27, 20223 (as amended to date, the “Consultancy Agreement”), by and between 180 Life Sciences Corp., a Delaware corporation (the “Company” or “180 LS”), Prof Jagdeep Nanchahal (the “Consultant”), and CannBioRex Pharma Limited, a subsidiary of the Company (“CannBioRex UK”). Certain capitalized terms used below but not otherwise defined shall have the meanings given to such terms in the Consultancy Agreement. The Company and CannBioRex UK together shall also be referred to as the “Group Company.”
